Search Back New search Go to resultsDiseaseMain groupHematological Diseases, Non-MalignantProtocol groupAnemias, CytopeniasHemolytic DiseasesDiseaseParoxysmal Nocturnal HemoglobinuriaSubgroupICD10D59.5MeSHHemoglobinuria, ParoxysmalSequenceCROV(1000/340), PNH, C1 (PID2729) -|- CROV680, PNH, C2+ (PID2730)ChemotherapyChemo-substanceDanicopanPegcetacoplanRavulizumabChemo-substanceDanicopanPegcetacoplanRavulizumabChemo-substanceDanicopanPegcetacoplanRavulizumabChemo-substanceDanicopanPegcetacoplanRavulizumabNo. Substances12 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionCrovalimabDanicopanEculizumabIptacopanRavulizumabSupportive substanceBalanced Crystalloid SolutionCrovalimabDanicopanEculizumabIptacopanRavulizumabSupportive substanceBalanced Crystalloid SolutionCrovalimabDanicopanEculizumabIptacopanRavulizumabSupportive substanceBalanced Crystalloid SolutionCrovalimabDanicopanEculizumabIptacopanRavulizumabNo. Substances123Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationFirst lineSecond lineseveral possibleTherapy phaseInductionMaintenanceTherapy intentiondisease controlpalliativeRisksAnemia Hb below 8g/dlAnemia Hb below 10g/dlArthalgiaAstheniaConstipationDiarrheaFatigueHeadacheHematotoxicityIncrease AminotransferasesInfectionsNasopharyngitisNauseaNeutropeniaPainPyrexiaRashThrombocytopenia below 50 000/µlUpper Respiratory Tract InfectionVomiting only studiesPublicationAuthorHillmen PLee JLee J / Kulasekararaj APeffault de Latour R Scheinberg PDiseasemind. 4 vorangegeangene Transfusionen in den letzten 12 Monaten, mind. 10% PNH Zellen und 100.000 Thrombozyten/µlmind. 4 vorangegegangene Transfusionen in den letzten 12 Monaten, mind. 10% PNH Zellen und 100.000 Thrombozyten/µlParoxysmale nächtliche Hämoglobinurie, mind. 10% PNH Zellen und 100.000 Thrombozyten/µlPNH, Erst-oder Zweitlinie nach EculizumabPNH, Klongröße mind 10%, Hämoglobinwert unter 10 g/dlPNH mit extravasaler Hämolyse, Patienten mindestens 6 Monate unter EculizumabPNH mit Hämoglobin < 10,5g/dl während 3 Monaten EculizumabOrigin301/302 studyBexley Wing, St. James’s University Hospital, Leeds, United Kingdom, Pegasus trialCOMMODORE 1/2Leeds General Infirmary, Leeds, United Kingdom, TRIUMPHSeoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, ALPHA, ALXN2040-PNH-301Universite de Paris, Saint-Louis Hospital, Paris, France, APPOINT-PNH trialProtocols in Revision 10 protocols foundProtocols under revision.Crovalimab (1000/340), Paroxysmal Nocturnal Hemoglobinuria, Cycle 1 (PID2729 V1.0)Crovalimab 680, Paroxysmal Nocturnal Hemoglobinuria, Cycle 2+ (PID2730 V1.0)Eculizumab 600, Paroxysmal Nocturnal Hemoglobinuria, Induction (PID791 V1.0)Eculizumab 900 / Danicopan 150, Paroxysmal Nocturnal Hemoglobinuria (PID2665 V1.0)Eculizumab 900, Paroxysmal Nocturnal Hemoglobinuria, maintenance (PID792 V1.0)Iptacopan 200, Paroxysmal Nocturnal Hemoglobinuria (PID2669 V1.0)Pegcetacoplan 1080, Paroxysmal Nocturnal Hemoglobinuria (PID1928 V1.0)Ravulizumab 2700, Paroxysmal Nocturnal Hemoglobinuria, Induction (PID1449 V1.0)Ravulizumab 3300 / Danicopan 150, Paroxysmal Nocturnal Hemoglobinuria (PID2701 V1.0)Ravulizumab 3300, Paroxysmal Nocturnal Hemoglobinuria, maintenance (PID1450 V1.0)
